Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres

Ekblad, Torun and Schüler, Herwig LU orcid (2016) In Chemical Biology and Drug Design 87(3). p.82-478
Abstract

PARP-family ADP-ribosyltransferases (PARPs) and sirtuin deacetylases all use NAD(+) as cosubstrate for ADP-ribosyl transfer. PARP inhibitors are important research tools and several are being evaluated in cancer treatment. With the exception of a few tankyrase inhibitors, all current PARP inhibitors mimic the nicotinamide moiety in NAD(+) and block the nicotinamide binding pocket. We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939. These findings indicate that PARP inhibitors containing... (More)

PARP-family ADP-ribosyltransferases (PARPs) and sirtuin deacetylases all use NAD(+) as cosubstrate for ADP-ribosyl transfer. PARP inhibitors are important research tools and several are being evaluated in cancer treatment. With the exception of a few tankyrase inhibitors, all current PARP inhibitors mimic the nicotinamide moiety in NAD(+) and block the nicotinamide binding pocket. We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939. These findings indicate that PARP inhibitors containing planar nicotinamide mimetics do not bind to sirtuin cofactor sites. In conclusion, a simple commercially available assay can be used to rule out interference of novel PARP inhibitors with sirtuin NAD(+) binding.

(Less)
Please use this url to cite or link to this publication:
author
and
publishing date
type
Contribution to journal
publication status
published
keywords
Humans, Niacinamide/chemistry, Poly(ADP-ribose) Polymerase Inhibitors/chemistry
in
Chemical Biology and Drug Design
volume
87
issue
3
pages
5 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:84960351219
  • pmid:26518726
ISSN
1747-0285
DOI
10.1111/cbdd.12680
language
English
LU publication?
no
additional info
© 2015 John Wiley & Sons A/S.
id
da5d5766-7be5-4a52-813d-30f6ef9968fd
date added to LUP
2024-11-21 17:53:16
date last changed
2025-05-09 22:32:36
@article{da5d5766-7be5-4a52-813d-30f6ef9968fd,
  abstract     = {{<p>PARP-family ADP-ribosyltransferases (PARPs) and sirtuin deacetylases all use NAD(+) as cosubstrate for ADP-ribosyl transfer. PARP inhibitors are important research tools and several are being evaluated in cancer treatment. With the exception of a few tankyrase inhibitors, all current PARP inhibitors mimic the nicotinamide moiety in NAD(+) and block the nicotinamide binding pocket. We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939. These findings indicate that PARP inhibitors containing planar nicotinamide mimetics do not bind to sirtuin cofactor sites. In conclusion, a simple commercially available assay can be used to rule out interference of novel PARP inhibitors with sirtuin NAD(+) binding.</p>}},
  author       = {{Ekblad, Torun and Schüler, Herwig}},
  issn         = {{1747-0285}},
  keywords     = {{Humans; Niacinamide/chemistry; Poly(ADP-ribose) Polymerase Inhibitors/chemistry}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{82--478}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Chemical Biology and Drug Design}},
  title        = {{Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres}},
  url          = {{http://dx.doi.org/10.1111/cbdd.12680}},
  doi          = {{10.1111/cbdd.12680}},
  volume       = {{87}},
  year         = {{2016}},
}